The purpose of this study is to assess the safety and effectiveness of rilpivirine hydrochloride in combination with other anti-retroviral (ARV) medications for the treatment of ARV-naive (patients who have not been exposed to ARV) Filipino patients with human immunodeficiency virus type 1 (HIV-1) infection.
No linked publications found in PubMed
Inclusion Criteria: * Filipino patients * ARV naive patients with HIV-1 infection who are assessed by the physician to be eligible for treatment with ARVs * Patients who voluntarily signed the informed consent form Exclusion Criteria: * Patients receiving drugs known to prolong QTc intervals, medicinal products with a known risk of Torsade de Pointes and anticonvulsants, systemic dexamethasone, proton pump inhibitors * Any previous treatment for HIV * Previously documented HIV-2 infection * Patients with viral load of \>100,000 HIV-1 ribo nucleic acid (RNA) copies/ml * Severely ill patients like those with acute acquired immune deficiency syndrome (AIDS)-defining illness or other major concomitant - disease prior to enrolment * Patients with severe hepatic impairment * Known hypersensitivity to rilpivirine hydrochloride * Pregnant or breastfeeding females